London: GSK plc has announced that Luke Miels has been appointed CEO Designate, GSK. Luke joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines. He has been instrumental in building GSK’s specialty medicines portfolio, notably in oncology and respiratory. “I am delighted to announce that Luke will be the next CEO of GSK. GSK is a very special company, with outstanding prospects and enormous capacity to impact people’s health and to change lives.